Blog

May 18

Clinicians’ Perspectives on Mifepristone Regulations in Primary Care

This publication details an exploratory study of US primary care clinicians’ perspectives on the effects of mifepristone restrictions, including US Food and Drug Administration (FDA) regulations, on access to medication abortion and early pregnancy loss (EPL) management in primary care. Protocols including mifepristone are the most effective medication regimens for medication abortion and EPL management.…

May 18

Contraceptive Pearls: Post Abortion Contraception

Most people ovulate 9-14 days after an abortion. Patients presenting to end a pregnancy may be interested in starting or changing their contraceptive method. Depending on a patient’s medical eligibility, the following contraceptive methods are safe and effective post-abortion: Estrogen/progestin pill, patch, ring Progestin-only pill, injection, implant, IUD Copper IUD Barrier methods Sterilization Fertility Awareness…

May 13

National LGBTQIA+ Health Education Center

This website, developed by the Fenway Institute, contains an extensive library of learning modules, videos, webinars, and other resources to support health care organizations optimize quality, cost-effective, and dignified care for lesbian, gay, bisexual, transgender, queer, intersex, asexual, and all sexual and gender minority (LGBTQIA+) people.  Link: https://www.lgbtqiahealtheducation.org/resources/  

Mar 16

Contraceptive Pearls: Progestin Contraceptives and Ulipristal to Treat Uterine Fibroids

Do progestin contraceptives help control the symptoms of fibroids? A recently updated Cochrane review addressed this question. The review examined four studies of 221 premenopausal patients with symptomatic fibroids. The results were inconclusive, with uncertainty about progestins’ effects on uterine bleeding and fibroid size. Ulipristal, on the other hand, showed more promise. A study of…